Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 4/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22026760 | 1.00 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22026762 | 1.00 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22127964 | 1.00 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22127923 | 0.98 | TLR2 (0.43) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22127922 | 0.98 | TLR2 (0.43) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22127920 | 0.98 | TLR2 (0.43) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL23039369 | 0.94 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL23039367 | 0.94 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL23039371 | 0.94 | TLR2 (0.46) | TLR2TLR1KMT2AMEN1ITGB3 | |
| SCHEMBL22127822 | 0.92 | KMT2A (0.43) | TLR2TLR1KMT2AMEN1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| EP-3668837-B1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPHARMA LTD (KY) | 2022-07-06 | — | — | EP | disclosed |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2021-02-18 | — | — | US | disclosed |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XW LABORATORIES INC. (KY) | 2020-12-08 | — | — | US | disclosed |
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | TLR2 1569/4885TLR1 751/4885KMT2A 4408/4885 |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | TLR2 1569/4885TLR1 751/4885KMT2A 4408/4885 |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | TLR2 1569/4885TLR1 751/4885KMT2A 4408/4885 |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | TLR2 1569/4885TLR1 751/4885KMT2A 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.